Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EZH2 promotes malignant phenotypes and is a predictor of oral cancer development in patients with oral leukoplakia.

Cancer prevention research (Philadelphia, Pa.) - 1 Nov 2011

Cao Wei, Younis Rania H, Li Jiang, Chen Haiyan, Xia Ronghui, Mao Li, Chen Wantao, Ren Hening

Abstract excerpt

Oral leukoplakia (OL) is the most common premalignancy in the oral cavity. A small proportion of OLs progresses to oral squamous cell carcinoma (OSCC). To assess OSCC risk of OLs, we investigated the role of the transcriptional repressor enhancer of zeste homolog 2 (EZH2) in oral tumorigenesis and its clinical implication as an OSCC risk predictor. Immunohistochemistry was used to measure EZH2 expression in OLs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Adhesion
Share to Enhancer of Zeste Homolog 2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoenzyme Techniques

Share to Leukoplakia, Oral

Share to Mouth Neoplasms

Share to Neoplasm Invasiveness

Share to Polycomb Repressive Complex 2

Share to RNA, Small Interfering

Source

Open in PubMed Open full text

Identifiers

PMID: 21697275
DOI: 10.1158/1940-6207.CAPR-11-0130
PMCID: PMC3677701

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EZH2 promotes malignant phenotypes and is a predictor of oral cancer development in patients with oral leukoplakia.PMID 21697275Read ↗

EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?Semantic proximity Read ↗

Aberrant Epigenetic Regulation in Head and Neck Cancer Due to Distinct EZH2 Overexpression and DNA Hypermethylation<strong> </strong>Semantic proximity Read ↗

Chromosomal Alterations and Gene Expression Changes Associated with the Progression of Leukoplakia to Advanced Gingivobuccal CancerSemantic proximity Read ↗

EZH2 knockout in oral cavity basal epithelia causes more invasive squamous cell carcinomas.Semantic proximity Read ↗

Association of EZH2 Genotypes With Oral Cancer Risk.Semantic proximity Read ↗

EZH2 Promotes Cholangiocarcinoma Development and Progression through Histone Methylation and microRNA-Mediated Down-Regulation of Tumor Suppressor GenesSemantic proximity Read ↗

Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.Semantic proximity Read ↗

Mutations in EZH2 are associated with poor prognosis for patients with myeloid neoplasmsSemantic proximity Read ↗

High-risk oral leukoplakia is associated with aberrant promoter methylation of multiple genesSemantic proximity Read ↗

Expression Profiling of EMT Transcriptional Regulators ZEB1 and ZEB2 in Different Histopathological Grades of Oral Squamous Cell Carcinoma PatientsSemantic proximity Read ↗

EZH2 promotes the expression of LPA1 by mediating microRNA-139 promoter methylation to accelerate the development of ovarian cancerSemantic proximity Read ↗

Methyltransferase-independent function of enhancer of zeste homologue 2 maintains tumorigenicity induced by human oncogenic papillomavirus and polyomavirusSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.